Wolchok JD, Kluger H, Callahan, MK, Postow, MA, Rizvi NA, Lesokhin, AM, Segal NH, Ariyan CE, Gordon RA, Reed, K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta, MA, Sznol M. Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients. New Engl J of Med. In press.